Source: StreetInsider

Press Release: Elevar Therapeutics : Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma

Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for...

Read full article »
Elevar Therapeutics's Competitors | Elevar Therapeutics's News | Elevar Therapeutics's Financials
Stay up-to-date with the latest news on Elevar Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Kate Flavin McKinley's photo - CEO of Elevar Therapeutics

CEO

Kate Flavin McKinley

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Elevar Therapeutics